CDK7

[Experimental Cell Research] Researchers studied the outcomes of olfactomedin 4 downregulation in human immortalized keratinocytes – the HaCaT cells.

[Science Translational Medicine] Disruption of the super-enhancer-associated gene transcription by THZ1, a covalent cyclin-dependent kinase 7 inhibitor, efficiently eradicated leukemia stem cells in retroviral BCR-ABL–driven chronic myelogenous leukemia mice while sparing normal hematopoietic stem cells.

[Journal of Biological Chemistry] The authors utilized TNBC as a model to discern mechanisms of resistance as it has been previously shown to be highly responsive to CDK7 inhibitors. After generating cell lines with acquired resistance, high throughput RNA-sequencing revealed significant upregulation of genes associated with efflux pumps and transforming growth factor-beta (TGF-β) signaling pathways.

[Carrick Therapeutics] Carrick Therapeutics announced that the US FDA has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2- advanced breast cancer and samuraciclib in combination with chemotherapy for the treatment of locally advanced or metastatic TNBC.

[Carrick Therapeutics (Globe Newswire, Inc.)] Carrick Therapeutics announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer.

[EMBO Reports] The authors showed that dedifferentiation of melanocytic-type melanoma cells into mesenchymal-like cells and acquisition of tolerance to targeted therapies was achieved through chronic inhibition of CDK7.